• 4TECH TriCinch™ System

    Designed to Simplify Transcatheter
    Tricuspid Valve Repair


Tricuspid Regurgitation :

Tricuspid regurgitation (TR) is a disorder in which the heart’s tricuspid valve does not close properly, causing blood to flow backward (leak) into the right upper heart chamber (atrium) when the right lower heart chamber (ventricle) contracts, reducing its efficiency1. Severe TR affects more than 1.6 million patients in the U.S. today2.

1 https://www.mayoclinic.org/diseases-conditions/tricuspid-valve-regurgitation/symptoms-causes/syc-20350168
2 Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg 2006;132:1258–61.


A Patient’s Perspective :

Watch this video on how the TriCinch System has transformed the life of a patient treated at Clinique Pasteur, Toulouse France.


Our Technology :

The TriCinch System is an antero-posterior annuloplasty solution for treating functional tricuspid regurgitation.



4TECH Inc. Reports First U.S. Clinical Implantations of Its TriCinch™ Tricuspid Valve Repair System

4TECH Inc., a leader in the field of transcatheter tricuspid valve repair, initiated its U.S. Early Feasibility Study, following receipt of approval from the U.S. Food and Drug Administration (FDA), with the successful first two implantations of the TriCinch™ System at Piedmont Heart Hospital, Atlanta, Georgia, by Dr. Christopher Meduri, Dr. Vivek Rajagopal and Dr.

Find out more

4Tech Inc. Appoints Tom Fleming as President and CEO, and Dr. Keith Dawkins as CMO

Tom Fleming replaces Mike Ennen, who is stepping down for family reasons. This new leadership team enhances the company’s strategy to advance its clinical program for TriCinch™ Tricuspid Valve Repair System.

Find out more

4Tech elects ex – Medtronic CEO William (“Bill”) A. Hawkins as its Chairman

4Tech elects ex-Medtronic CEO William (“Bill”) A. Hawkins as its Chairman

Find out more